This study will evaluate the efficacy and safety of concurrent chemoradiotherapy（CCRT）followed by cadonilimab（AK104) in high risk local advanced cervical cancer.
Participants received CCRT，efficacy evaluation of CCRT was no disease progression who maintained with AK104（10.0 mg/kg，Q3W）until drug exposure over 1 years or disease progression or intolerable toxicity.
Voluntary agreement to provide written informed consent.
female, Age 18 -75 years.
Predicted survival ≥ 3 month.
Histologically and/or cytologically confirmed Squamous cell carcinoma, adenocarcinoma, adenosquamous cell carcinoma, FIGO 2018 stage III-IVA.
Has received other antitumor therapy before CCRT.
Therapeutic evaluation of CCRT was disease progression.
Previously received immune checkpoint inhibitors (such as anti-PD-1 antibodies, anti-PD-L1 antibodies, anti-CTLA-4 antibodies, etc.), immune checkpoint agonists (such as ICOS, CD40, CD137, GITR, and Ox40 . etc.), immune cell therapy. etc. Any tumor immune mechanisms treatment .
With brain metastases.
West China Second University Hospital
Lead sponsor
Affiliated Hospital of North Sichuan Medical College
Collaborator
The Affiliated Hospital Of Southwest Medical University
Collaborator